Clinical trials: Flu
Healthy
A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine
This prospective annual release study was designed to assess the safety of a monovalent influenza virus vaccine using a new strain recommended for the 2009-2010 influenza season not previously contained in the trivalent…
- Trial name
- MI-MA205 (NCT00873912)
- Testing
- Monovalent influenza virus vaccine
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Pneumonia
Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age.
- Conditions
- Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction
- Trial name
- NCT03694392
- Testing
- Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
- Where
- United States
- Volunteers
- 2,776,278 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Influenza
Influenza Antiviral DAS-181-F04 in Healthy Adults
This study will be a double-blind, randomized, placebo-controlled study of a single dose (20mg) of Influenza Antiviral DAS181-F04 for 3 days.
- Trial name
- NCT01651494
- Testing
- DAS181
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Study of a Pandemic Influenza Vaccine in Elderly Participants
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is one of the leading candidates to cause the next influenza pandemic.
- Trial name
- NCT00376402
- Testing
- H5N1 Pandemic Influenza Vaccine
- Where
- 2 sites in Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly
The objective of the study is to evaluate immunogenicity between different formulations of GSK Biologicals' investigational vaccine GSK2186877A.
- Trial name
- NCT00938392
- Testing
- GSK investigational FluNG vaccine GSK2186877A, aged lot, GSK investigational FluNG vaccine GSK2186877A, fresh lot
- Where
- 6 sites in Estonia, Slovakia
- Volunteers
- 726 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Stroke, Influenza Human
Vaccination Nudges From Pharmacists
The goal of this individual-level pragmatic randomized policy trial is to learn about the impact of behavioural nudges via mailed letters on increasing influenza and travel vaccination uptake in Alberta, Canada.
- Conditions
- Stroke, Influenza Human, Influenza Vaccines, Health Behavior Change
- Trial name
- NCT07161739
- Testing
- Behavioural Nudge (Influenza Risk Reduction), Behavioural Nudge (Travel Vaccination Benefit)
- Where
- Canada
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Immunosenescence
Pilot Study on Effect Size of Non-digestible Polysaccharides (NPS) on Immunity
The aim of the study is to estimate the effect size of a 5-week consumption period of different dietary non-digestible polysaccharides (NPS) on antibody response to influenza vaccination and cellular immunity of healthy…
- Trial name
- Fib-P-2012 (NCT01896154)
- Testing
- NPS
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Clinical Research Center Kiel GmbH
Healthy
Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children
The study was designed to determine the number of doses of CAIV-T required to effectively immunize children and adolescents in the 6 to 17 year age group.
- Trial name
- FluMist (NCT00192270)
- Testing
- CAIV-T
- Where
- 3 sites in Belgium, Finland
- Volunteers
- 498 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults
The study will assess the safety, reactogenicity, and tolerability of VAX102 when given with Trivalent Inactivated Influenza Vaccine (TIV) delivered in the same arm as two separate IM injections in healthy adults 18 to 49 years.
- Trial name
- NCT00921973
- Testing
- VAX102
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Influenza
Proteomic Profiling for Influenza Vaccination - FluMist
The purpose of this study is to look at changes that occur in blood and nasal swab samples after a person's immune system responds to receiving a flu vaccine.
- Trial name
- NCT00385281
- Testing
- FluMist
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
2010/2011 Trivalent Influenza Vaccination
Intradermal influenza vaccination may result in better efficacy when compare to intramuscular vaccination.
- Trial name
- NCT01304563
- Testing
- TIV 2010/2011 influenza vaccine, INT
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Influenza Immunization
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5413 compared to an…
- Trial name
- NCT05650554
- Testing
- Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
H9 Priming Study in Healthy Adults
The purpose of this research study is to determine whether prior exposure to A/H2N2 viruses is associated with better antibody (part of the immune system that fights infection) responses after vaccination with an A/H9N2 flu…
- Trial name
- NCT00617331
- Testing
- Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.
The purpose of the AcRIS study is to obtain data to characterize the relationship between symptoms and voice features for (reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome…
- Trial name
- NCT04748445
- Testing
- SARS-CoV-2/Influenza/RSV RT-PCR
- Where
- United States
- Volunteers
- 9,151 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older
The primary efficacy objective is to demonstrate the efficacy of aCoV2 versus a placebo to prevent the first occurrence of virologically-confirmed symptomatic COVID 19 according to the European Centre for Disease Prevention and…
- Trial name
- NCT04806529
- Testing
- Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2), Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seqirus
Orthomyxoviridae Infection, Influenza
Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults
The primary objective of this trial is to demonstrate the equivalence, in terms of immunogenicity, of three different industrial lots of the investigational vaccine thereby supporting consistency of the manufacturing process.
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00383539
- Testing
- Inactivated Split-virion influenza vaccine
- Where
- 4 sites in France, Lithuania and 2 more
- Volunteers
- 2,256 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.
- Trial name
- NCT01236040
- Testing
- GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A
- Where
- 4 sites in United States
- Volunteers
- 521 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
The purpose of this study is to assess the reactogenicity, safety and immunogenicity of different formulations of GlaxoSmithKline (GSK) Biologicals' investigational supra-seasonal universal influenza vaccines (SUIVs)…
- Trial name
- NCT03275389
- Testing
- D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03
- Where
- 6 sites in United States, Belgium
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
- Trial name
- NCT00765076
- Testing
- GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix
- Where
- 4 sites in United States, Spain
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses
A single center trial to evaluate the effect of POLB 001 on inflammatory responses following an intradermal LPS challenge in healthy volunteers.
- Trial name
- NCT05765955
- Testing
- POLB 001
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Poolbeg Pharma plc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.